Jove
Visualize
Contact Us

Related Experiment Videos

Clinical trial design for evaluating combination therapies

H E Paulus1

  • 1University of California, Los Angeles, USA.

British Journal of Rheumatology
|November 1, 1995
PubMed
Summary

Proving the benefits of combination disease-modifying antirheumatic drugs (DMARDs) is challenging. Optimized study designs, including specific patient selection and outcome measures, are crucial for detecting true treatment benefits in rheumatoid arthritis (RA) trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TJ-114 (Sairei-To), an Herbal Medicine in Rheumatoid Arthritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort.

Arthritis and rheumatism·2007
Same author

Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument.

Arthritis and rheumatism·2006
Same author

Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice.

Arthritis and rheumatism·2006
Same author

ACR remission criteria and response criteria.

Clinical and experimental rheumatology·2006
Same author

Consensus recommendations for the assessment and treatment of rheumatoid arthritis.

The Journal of rheumatology·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Rheumatology
  • Clinical Trial Design
  • Pharmacology

Background:

  • Demonstrating additive or synergistic benefits of combination disease-modifying antirheumatic drugs (DMARDs) over monotherapy is difficult due to small expected efficacy differences.
  • Existing study designs often lack the discriminatory power to detect subtle improvements in rheumatoid arthritis (RA) treatment.

Purpose of the Study:

  • To outline methods for enhancing the discriminatory power of clinical trials evaluating DMARD combinations.
  • To improve the ability to detect true clinical benefits of DMARD combinations in rheumatoid arthritis (RA).

Main Methods:

  • Careful patient selection and optimization of study design, duration, and analytical methods.
  • Utilizing the American College of Rheumatology (ACR) 'core set' of outcome measures and proposed 'definition of improvement'.
  • Conducting balanced, prospective, double-blind randomized clinical trials of 1-2 years duration with intent-to-treat analysis.

Main Results:

  • The proposed methodological enhancements are expected to increase the likelihood of discriminating between combination DMARD therapy and its components.
  • Optimized trial designs increase the power to detect real differences in clinical benefit.

Conclusions:

  • Rigorous study design is essential for accurately assessing the efficacy of combination DMARDs in RA.
  • Specific methodological choices, including outcome measures and trial duration, significantly impact the ability to demonstrate treatment benefits.

Related Experiment Videos